Enzolytics Inc. Launches Coronavirus Prevention Kit

MONROVIA, CA – February 4, 2020 – Enzolytics Inc. (OTC: ENZC) today announced the launched of the coronavirus prevention kit. The coronavirus prevention kit will contain the following face mask, hand sanitizer, rubber gloves and eye goggles. The kit will help to prevent the infection and limit the spread. The kit will be available through our web site (www.enzolytics.com) in the coming days.

As of February 3, 2020 the coronavirus has spread to 24 other countries and has reportedly killed 362 people in China and one person in the Philippines.

The CDC said to prevent the coronavirus people should stick to the tried-and-true methods they would use to avoid any virus. These suggestions include:

  • Avoiding close contact with people who are infected.
  • If you’re sick, avoid interacting with other people.
  • Don’t go to work if you’re sick; stay home.
  • When you sneeze, cover your nose and mouth.
  • Try not to touch your eyes, nose, and mouth.
  • Regularly clean and disinfect surfaces and objects that could be contaminated with germs (like your phone).
  • Regularly wash your hands with soap and water for 20 seconds or more, or use an alcohol-based sanitizer with 60% alcohol or higher if you can’t get to a sink.

About Enzolytics Inc.:

Enzolytics Inc.is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind.

Enzolytics Inc. flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.

Safe Harbor Statement:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics Inc., from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.

Enzolytics Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics Inc. to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests.

Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Enzolytics Inc. or any other person that the objectives and plans of Enzolytics Inc. will be achieved should not regard the forward-looking statements as a representation.

Media Contact
Company Name: Enzolytics Inc.
Contact Person: IR
Email: Send Email
Phone: (626) 538-4779
Country: United States
Website: www.enzolytics.com